Impedimed (ASX:IPD) PEG Ratio: 0.00 (As of Jun. 26, 2026)


What is Impedimed PEG Ratio?

Impedimed ASX:IPD PEG Ratio is 0.00 as of Jun. 26, 2026. The stock has 6 warning signs investors should review. Among 208 Medical Devices & Instruments companies, Impedimed ranks worse than 480768.75% on this metric.

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Impedimed's PE Ratio without NRI is 0.00. Impedimed's 5-Year EBITDA growth rate is 22.80%. Therefore, Impedimed's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Impedimed's PEG Ratio or its related term are showing as below:



ASX:IPD's PEG Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.915
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Impedimed  (ASX:IPD) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Impedimed PEG Ratio Related Terms


Impedimed PEG Ratio Historical Data

* Premium members only.

The historical data trend for Impedimed's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Impedimed PEG Ratio Chart

Impedimed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Impedimed Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:IPD vs ABT, SYK, MDT: PEG Ratio Comparison

For the Medical Devices subindustry, Impedimed's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Impedimed PEG Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Impedimed's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Impedimed's PEG Ratio falls into.



Impedimed PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Impedimed's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/22.80
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Frequently Asked Questions Learn more about PEG Ratio →
What does a PEG Ratio of 0.00 mean?
Impedimed (ASX:IPD) has a PEG Ratio of 0.00 as of Jun. 26, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Impedimed and its competitors. According to the industry distribution chart, Impedimed ranks #999999 out of 208 companies in the Medical Devices & Instruments industry.
Is Impedimed's PEG Ratio too high?
Impedimed's current PEG Ratio is 0.00. Based on the distribution chart, Impedimed ranks #999999 out of 208 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Impedimed's PEG Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Impedimed ranks #999999 out of 208 companies for PEG Ratio. This places Impedimed in the lower half of its industry. The industry median PEG Ratio is 1.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Medical Devices & Instruments company?
The median PEG Ratio among Medical Devices & Instruments companies is 1.92, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Impedimed and its competitors. For the Medical Devices & Instruments industry, the median PEG Ratio is 1.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Impedimed's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Impedimed stock overvalued right now?
Based on GuruFocus' analysis, Impedimed (ASX:IPD) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.08, compared to a current price of A$0.01 — trading 93.8% below its estimated fair value. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Impedimed (ASX:IPD), the current PEG Ratio is 0.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Impedimed Business Description

Other Exchanges IPDQF:USA
Address 5900 Pasteur Court, Suite 125, Carlsbad, CA, USA, 92008
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.